PHILADELPHIA — The investigational drug verekitug improved sinonasal symptoms, reduced nasal polyp size, and reduced the need for nasal polyp surgery in people with chronic rhinosinusitis with nasal ...
The oncology monoclonal antibodies market presents opportunities through technological advancements, new product launches, ...
A monoclonal antibody created by the Nanobiotechnology for Diagnostics group (Nb4D) at the Institute of Advanced Chemistry of ...
NEW HAVEN, Conn., March 05, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced financial results for the fourth quarter and full year ended December 31, 2025, and recent business ...
Forte Biosciences, Inc. ( (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with ...
Invivyd, Inc. has launched a discovery program for a monoclonal antibody (mAb) targeting measles, following requests from healthcare providers for a treatment option for active infections and ...
Approximately 40% of the European population is allergic to pollen, and their symptoms cause the estimated loss of 100 million school and work days every year. Traditional treatment is ...
The investigational monoclonal antibody clesrovimab protected against respiratory syncytial virus (RSV) disease and prevented RSV hospitalizations among healthy preterm- and term infants, according to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results